Compare Stocks: APTO, AUTL, and MGTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APTO Aptose Biosciences	$1.71	$4.41	$1.35 ▼ $50.10	$3.66M	1.04	227,964 shs	N/A
AUTL Autolus Therapeutics	$2.33 -4.7%	$1.76	$1.17 ▼ $2.58	$618.82M	2.07	1.81 million shs	650,681 shs
MGTX MeiraGTx	$14.50 -2.8%	$12.79	$6.62 ▼ $15.35	$1.39B	1.23	711,895 shs	219,585 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APTO Aptose Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
AUTL Autolus Therapeutics	+4.27%	+6.55%	+68.28%	+45.24%	+52.50%
MGTX MeiraGTx	+0.61%	+7.42%	+26.76%	+50.86%	+96.83%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APTO Aptose Biosciences	$1.71	$4.41	$1.35 ▼ $50.10	$3.66M	1.04	227,964 shs	N/A
AUTL Autolus Therapeutics	$2.33 -4.7%	$1.76	$1.17 ▼ $2.58	$618.82M	2.07	1.81 million shs	650,681 shs
MGTX MeiraGTx	$14.50 -2.8%	$12.79	$6.62 ▼ $15.35	$1.39B	1.23	711,895 shs	219,585 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APTO Aptose Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
AUTL Autolus Therapeutics	+4.27%	+6.55%	+68.28%	+45.24%	+52.50%
MGTX MeiraGTx	+0.61%	+7.42%	+26.76%	+50.86%	+96.83%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APTO Aptose Biosciences	0.00	N/A	N/A	N/A
AUTL Autolus Therapeutics	2.88	Moderate Buy	$10.00	330.11% Upside
MGTX MeiraGTx	3.00	Buy	$26.17	80.41% Upside

Current Analyst Ratings Breakdown

Latest APTO, AUTL, and MGTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	MGTX MeiraGTx	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$26.00 ➝ $27.00
8/13/2026	AUTL Autolus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	MGTX MeiraGTx	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/3/2026	AUTL Autolus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
7/31/2026	AUTL Autolus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	MGTX MeiraGTx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/8/2026	MGTX MeiraGTx	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$25.00 ➝ $26.00
7/8/2026	MGTX MeiraGTx	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
7/6/2026	AUTL Autolus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/17/2026	AUTL Autolus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/29/2026	AUTL Autolus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	($0.19) per share	N/A
AUTL Autolus Therapeutics	$75.39M	8.21	N/A	N/A	$0.28 per share	8.30
MGTX MeiraGTx	$81.39M	17.11	N/A	N/A	$2.25 per share	6.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APTO Aptose Biosciences	-$51.21M	-$89.19	N/A	N/A	N/A	N/A	-5,683.22%	-300.44%	N/A
AUTL Autolus Therapeutics	-$287.53M	-$1.06	N/A	N/A	N/A	-238.66%	-178.66%	-49.34%	10/29/2026 (Estimated)
MGTX MeiraGTx	-$114.20M	$0.71	20.37	N/A	N/A	19.87%	283.85%	29.39%	11/12/2026 (Estimated)

Latest APTO, AUTL, and MGTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2026	Q2 2026	MGTX MeiraGTx	-$0.4583	$1.71	+$2.1683	$1.71	$0.70 million	$321.43 million
8/11/2026	Q2 2026	AUTL Autolus Therapeutics	-$0.21	-$0.15	+$0.06	-$0.15	$38.56 million	$45.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	N/A
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APTO Aptose Biosciences	N/A	1.05	1.05
AUTL Autolus Therapeutics	1.04	4.89	4.40
MGTX MeiraGTx	0.46	3.76	3.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APTO Aptose Biosciences	26.62%
AUTL Autolus Therapeutics	72.83%
MGTX MeiraGTx	67.48%

Insider Ownership

Company	Insider Ownership
APTO Aptose Biosciences	1.33%
AUTL Autolus Therapeutics	25.70%
MGTX MeiraGTx	7.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APTO Aptose Biosciences	31	2.14 million	63.45 million	No Data
AUTL Autolus Therapeutics	330	266.16 million	197.76 million	Optionable
MGTX MeiraGTx	300	96.04 million	88.94 million	Optionable

APTO, AUTL, and MGTX Headlines

Recent News About These Companies

Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical

2 hours ago | prnewswire.com

Tocqueville Asset Management L.P. Makes New $1.05 Million Investment in MeiraGTx Holdings PLC $MGTX

August 21, 2026 | marketbeat.com

What Does MeiraGTx (NASDAQ:MGTX) Reveal About Nasdaq Biotech Trends?

August 19, 2026 | kalkinemedia.comK

Insider Selling: MeiraGTx (NASDAQ:MGTX) CEO Sells $859,320.00 in Stock

August 19, 2026 | insidertrades.com

Alexandria Forbes Sells 62,000 Shares of MeiraGTx (NASDAQ:MGTX) Stock

August 18, 2026 | marketbeat.com

MeiraGTx (NASDAQ:MGTX) Price Target Raised to $27.00

August 17, 2026 | americanbankingnews.com

FY2026 EPS Estimates for MeiraGTx Increased by HC Wainwright

August 17, 2026 | marketbeat.com

Johnson & Johnson Takes $89.72 Billion Position in MeiraGTx Holdings PLC $MGTX

August 16, 2026 | marketbeat.com

MeiraGTx (NASDAQ:MGTX) Trading Up 8.4% on Earnings Beat

August 16, 2026 | americanbankingnews.com

What Could MeiraGTx Holdings (MGTX) New Hires And Profit Swing Signal?

August 15, 2026 | uk.finance.yahoo.com

MeiraGTx (NASDAQ:MGTX) Upgraded by Zacks Research to "Strong-Buy" Rating

August 15, 2026 | marketbeat.com

MeiraGTx (NASDAQ:MGTX) Raised to Buy at Wall Street Zen

August 15, 2026 | americanbankingnews.com

MeiraGTx (NASDAQ:MGTX) Upgraded by Wall Street Zen to "Buy" Rating

August 15, 2026 | marketbeat.com

MeiraGTx (NASDAQ:MGTX) Shares Gap Up on Earnings Beat

August 15, 2026 | americanbankingnews.com

MeiraGTx (NASDAQ:MGTX) Trading 8.4% Higher Following Strong Earnings

August 14, 2026 | marketbeat.com

MeiraGTx (NASDAQ:MGTX) Given New $27.00 Price Target at Royal Bank Of Canada

August 14, 2026 | marketbeat.com

MeiraGTx Swings to Q2 Profit, Revenue Rises

August 14, 2026 | finance.yahoo.com

Sei Investments Co. Buys Shares of 99,627 MeiraGTx Holdings PLC $MGTX

August 14, 2026 | marketbeat.com

MeiraGTx (NASDAQ:MGTX) Releases Quarterly Earnings Results, Beats Expectations By $2.17 EPS

August 13, 2026 | marketbeat.com

MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates

August 13, 2026 | zacks.com

MeiraGTx (NASDAQ:MGTX) Shares Gap Up on Strong Earnings

August 13, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APTO, AUTL, and MGTX Company Descriptions

Aptose Biosciences NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Autolus Therapeutics NASDAQ:AUTL

$2.33 -0.12 (-4.71%)

As of 01:10 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

MeiraGTx NASDAQ:MGTX

$14.50 -0.42 (-2.79%)

As of 01:11 PM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APTO, AUTL, and MGTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APTO, AUTL, and MGTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APTO, AUTL, and MGTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APTO, AUTL, and MGTX Company Descriptions

Aptose Biosciences NASDAQ:APTO

Autolus Therapeutics NASDAQ:AUTL

MeiraGTx NASDAQ:MGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APTO, AUTL, and MGTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APTO, AUTL, and MGTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APTO, AUTL, and MGTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APTO, AUTL, and MGTX Company Descriptions

Aptose Biosciences NASDAQ:APTO

Autolus Therapeutics NASDAQ:AUTL

MeiraGTx NASDAQ:MGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools